Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Lithium Ion. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CLTC | Q00610 | 9/20 | 0.44 |
| ▸ | CA1 | P00915 | 7/20 | 0.36 |
| ▸ | CA2 | P00918 | 7/20 | 0.36 |
| ▸ | CA12 | O43570 | 5/20 | 0.36 |
| ▸ | CA9 | Q16790 | 5/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | USP2 | O75604 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | KEAP1 | Q14145 | 2/20 | 0.35 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.35 |
| ▸ | CA7 | P43166 | 2/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Lithium Ion SCHEMBL95351 | 1.00 | CLTC (0.44) | CLTCCA1CA2CA12CA9 | |
| SCHEMBL28451650 | 0.86 | KMT2A (0.37) | CLTCCA1CA2CA12CA9 | |
| SCHEMBL28898006 | 0.85 | KMT2A (0.36) | CLTCCA1CA2CA12CA9 | |
| SCHEMBL13870630 | 0.79 | KMT2A (0.39) | CA1CA2CA12CA9MEN1 | |
| Lithium Ion SCHEMBL2890318 | 0.75 | CA1 (0.40) | CA1CA2CA12CA9CA7 | |
| SCHEMBL27851603 | 0.74 | NPC1 (0.42) | CA1CA2CA12CA9MEN1 | |
| SCHEMBL28312087 | 0.72 | KMT2A (0.34) | CLTCMEN1USP2KMT2AKEAP1 | |
| SCHEMBL31305335 | 0.71 | CA1 (0.50) | CA1CA2CA12CA9MEN1 | |
| Potassium Ion SCHEMBL4636440 | 0.69 | CLTC (0.46) | CLTCMEN1KMT2A | |
| Potassium Ion SCHEMBL31670338 | 0.69 | CLTC (0.46) | CLTCMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12578341-B2 | Iterative fluorescence imaging | Universität Zürich (CH) | 2026-03-17 | — | — | US | disclosed |
| EP-4673160-A1 | NON-COVALENT BINDING PEPTIDE AND CARRIER COMPLEX COMPRISING IT | Consejo Superior de Investigaciones Cientificas M.P. (ES) | 2026-01-07 | — | — | EP | disclosed |
| WO-2025233323-A1 | DETECTION OF PATHOGENIC E. COLI STRAINS | Universität Bern (CH) | 2025-11-13 | — | — | WO | disclosed |
| EP-3791863-B1 | PROCESS FOR THE PRODUCTION OF HYBRIDOSOMES | ANJARIUM BIOSCIENCES AG (CH) | 2025-09-10 | — | — | EP | disclosed |
| WO-2025120184-A1 | T CELL SPECIFIC DISPERSION CANCER BIOMARKER | Universität Zürich (CH) | 2025-06-12 | — | — | WO | disclosed |
| WO-2024179980-A1 | NON-COVALENT BINDING PEPTIDE AND CARRIER COMPLEX COMPRISING IT | CONSEJO SUPERIOR DE INVESTIGACIONES CIENTÍFICAS (ES) | 2024-09-06 | — | — | WO | disclosed |
| EP-4420670-A1 | NON-COVALENT BINDING PEPTIDE AND CARRIER COMPLEX COMPRISING IT | Consejo Superior De Investigaciones Científicas (ES) | 2024-08-28 | — | — | EP | disclosed |
| US-11944706-B2 | Hybridosomes, compositions comprising the same, processes for their production and uses thereof | ANJARIUM BIOSCIENCES AG (CH) | 2024-04-02 | — | — | US | disclosed |
| EP-4291901-A1 | USE OF MARKERS FOUND ON LYMPH NODE METASTATIC SAMPLES FOR THE PROGNOSIS OF BREAST CANCER | Universität Zürich (CH) | 2023-12-20 | — | — | EP | disclosed |
| US-20230181467-A1 | HYBRIDOSOMES, COMPOSITIONS COMPRISING THE SAME, PROCESSES FOR THEIR PRODUCTION AND USES THEREOF | ANJARIUM BIOSCIENCES AG (CH) | 2023-06-15 | — | — | US | disclosed |
| US-11484500-B2 | Hybridosomes, compositions comprising the same, processes for their production and uses thereof | ANJARIUM BIOSCIENCES AG (CH) | 2022-11-01 | — | — | US | disclosed |
| WO-2022171831-A1 | USE OF MARKERS FOUND ON LYMPH NODE METASTATIC SAMPLES FOR THE PROGNOSIS OF BREAST CANCER | Universität Zürich (CH) | 2022-08-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12578341-B2 | Iterative fluorescence imaging | FGB, CLTB, CD44 | CLTC 72/4885CA1 188/4885CA2 455/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.